Evidence map›Paper›PMID 34050452›Full record

ArticleBiochemical genetics2021

CircARL8B Contributes to the Development of Breast Cancer Via Regulating miR-653-5p/HMGA2 Axis.

Hansheng Wu, Jingyun Xu, Guoliang Gong, Yuanxin Zhang, Shenggui Wu

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Insights Into circRNA-Mediated Lipid Metabolism in Cancer Progression.Journal of cellular and molecular medicine · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. The emerging role and mechanism of HMGA2 in breast cancer.Journal of cancer research and clinical oncology · 2024
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hansheng Wu *Department of Thoracic Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
Jingyun Xu *Department of Pathology, The First Affiliated Hospital of Shantou University Medical College, No. 57, Changping Road, Shantou, 515041, Guangdong, China.
Guoliang GongDepartment of Pathology, The First Affiliated Hospital of Shantou University Medical College, No. 57, Changping Road, Shantou, 515041, Guangdong, China. blkggl@163.com.ORCID http://orcid.org/0000-0002-5636-7069
Yuanxin ZhangDepartment of Pathology, Chaonan Minsheng Hospital of Shantou, Shantou, Guangdong, China.
Shenggui WuDepartment of Pathology, Chaonan Minsheng Hospital of Shantou, Shantou, Guangdong, China.
Shantou University · CNShantou Central Hospital · CN

Funding

Guangdong Province Science and Technology Innovation Strategy Special Fund Shanfuke(2018) 157
6 · The paper itself

Abstract

Circular RNAs (circRNAs) act as essential regulators in breast cancer (BC) progression. In this paper, we aimed to investigate the functions of circARL8B in BC. The levels of circARL8B, ADP Ribosylation Factor Like GTPase 8B (ARL8B), miR-653-5p and high-mobility group AT-hook 2 (HMGA2) mRNA were examined by qRT-PCR. The stability of circARL8B was determined by RNase R assay and Actinomycin D assay. Cell viability and metastasis were evaluated by Cell Counting Kit-8 (CCK-8) assay and transwell assay, respectively. The levels of cellular phospholipids and triglycerides were measured using relevant kits. Protein levels were measured by western blot analysis. The association between miR-653-5p and circARL8B or HMGA2 was verified by dual-luciferase reporter assay. A murine xenograft model was established to explore the function of circARL8B in vivo. CircARL8B was increased in BC tissues and cells. CircARL8B silencing inhibited cell viability, migration, invasion and fatty acid metabolism in BC cells in vitro and blocked tumor growth in vivo. MiR-653-5p was identified as the target of circARL8B and miR-653-5p was negatively modulated by circARL8B. The suppressive role of circARL8B silencing in BC cell progression was abolished by miR-653-5p downregulation. Moreover, HMGA2 was the target gene of miR-653-5p. HMGA2 overexpression abrogated the effect of miR-653-5p on BC cell development. In addition, circARL8B knockdown might block PGE2/PI3K/AKT/GSK-3β/Wnt/β-catenin pathway. Silencing of circARL8B inhibited cell viability, migration, invasion and fatty acid metabolism via miR-653-5p/HMGA2 axis in BC.

Indexed as

Breast NeoplasmsMicroRNAsRNA, CircularADP-Ribosylation FactorsAnimalsCell ProliferationFemaleGene Expression Regulation, NeoplasticGlycogen Synthase Kinase 3 betaHeterograftsHMGA2 ProteinHumansMicePhosphatidylinositol 3-KinasesADP-Ribosylation FactorsGlycogen Synthase Kinase 3 betaHMGA2 ProteinHMGA2 protein, humanMicroRNAsMIRN653 microRNA, humanPhosphatidylinositol 3-KinasesRNA, CircularBreast cancercircARL8BHMGA2miR-653-5p

Identifiers

PMID34050452
OpenAlexW3165370299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.